Professor Kamil R. Kranc is the Chair of Haemato-Oncology and Director of the Centre for In Vivo Modelling at The Institute of Cancer Research (ICR) in London. Kamil graduated in medicine from the Medical University of Silesia (Poland) in 2000 and obtained a DPhil (PhD) in Biochemistry from the University of Oxford in 2003. He established his first lab as a Beit Memorial Fellow at Oxford, followed by group leader positions in Glasgow, Edinburgh, and London.
His central aim is to discover the key processes governing cancer stem cells in acute myeloid leukaemia (AML), with the goal of selectively targeting these treatment-resistant cells, thus pioneering curative, non-toxic therapies. Specifically, the Kranc lab focuses on the therapeutic targeting of diverse RNA modifications and metabolic pathways in AML.
The Kranc lab is supported by the CRUK Programme Grant, Barts Charity Research Grant, and the ICR.
